ATE545407T1 - Pharmazeutische formulierung von apomorphin für die bukkale verabreichung - Google Patents

Pharmazeutische formulierung von apomorphin für die bukkale verabreichung

Info

Publication number
ATE545407T1
ATE545407T1 AT06727033T AT06727033T ATE545407T1 AT E545407 T1 ATE545407 T1 AT E545407T1 AT 06727033 T AT06727033 T AT 06727033T AT 06727033 T AT06727033 T AT 06727033T AT E545407 T1 ATE545407 T1 AT E545407T1
Authority
AT
Austria
Prior art keywords
apomorphine
buccal administration
pharmaceutical formulation
formulation
pharmaceutically acceptable
Prior art date
Application number
AT06727033T
Other languages
English (en)
Inventor
Anthony Clarke
Original Assignee
Amarin Pharmaceuticals Ie Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Pharmaceuticals Ie Ltd filed Critical Amarin Pharmaceuticals Ie Ltd
Application granted granted Critical
Publication of ATE545407T1 publication Critical patent/ATE545407T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT06727033T 2005-05-06 2006-05-08 Pharmazeutische formulierung von apomorphin für die bukkale verabreichung ATE545407T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0509317.4A GB0509317D0 (en) 2005-05-06 2005-05-06 Pharmaceutical formulation of apomorphine
PCT/GB2006/001665 WO2006120412A1 (en) 2005-05-06 2006-05-08 Pharmaceutical formulation of apomorphine for buccal administration

Publications (1)

Publication Number Publication Date
ATE545407T1 true ATE545407T1 (de) 2012-03-15

Family

ID=34685218

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06727033T ATE545407T1 (de) 2005-05-06 2006-05-08 Pharmazeutische formulierung von apomorphin für die bukkale verabreichung

Country Status (20)

Country Link
US (2) US20090023766A1 (de)
EP (1) EP1885333B1 (de)
JP (1) JP5116665B2 (de)
KR (1) KR101365458B1 (de)
CN (1) CN101217936A (de)
AT (1) ATE545407T1 (de)
AU (1) AU2006245564A1 (de)
BR (1) BRPI0611258A2 (de)
CA (1) CA2607802C (de)
DK (1) DK1885333T3 (de)
ES (1) ES2383433T3 (de)
GB (1) GB0509317D0 (de)
IL (1) IL187183A0 (de)
MX (1) MX2007013890A (de)
NO (1) NO339404B1 (de)
PT (1) PT1885333E (de)
RU (1) RU2007140701A (de)
SI (1) SI1885333T1 (de)
WO (1) WO2006120412A1 (de)
ZA (1) ZA200709474B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0819530D0 (en) * 2008-10-24 2008-12-03 Univ Sheffield Methods and compositions
PT2952191T (pt) * 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
EP2651357B1 (de) * 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublinguale filme
EP2545788A1 (de) * 2011-07-13 2013-01-16 Martin Hulliger Diätisches Mehrkomponentensystem
US20150328258A1 (en) * 2012-05-30 2015-11-19 Ibh Ventures, Llc Polyphenol-reactive oxygen species compositions and methods
WO2013183055A1 (en) 2012-06-05 2013-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
JP2016535794A (ja) 2013-11-11 2016-11-17 インパックス ラボラトリーズ，インコーポレーテッド 急速崩壊性製剤及びその使用法
JP6042794B2 (ja) * 2013-12-03 2016-12-14 本田技研工業株式会社 車両制御方法
US9682039B2 (en) * 2014-08-07 2017-06-20 Mucodel Pharma Llc Chemically stable and oromucosally absorbable gel compositions of a pharmaceutical active agent in a multi-chambered delivery system
US10493027B2 (en) 2014-08-07 2019-12-03 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery
EP4578461A3 (de) 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Verfahren zur behandlung von morbus parkinson durch verabreichung von apomorphin an die mundschleimhaut
US20180280465A1 (en) 2015-09-28 2018-10-04 Ever Neuro Pharma Gmbh Aqueous composition of apomorphine for subcutaneous administration
WO2018148382A1 (en) * 2017-02-10 2018-08-16 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
WO2023012736A1 (en) * 2021-08-05 2023-02-09 Zydus Lifesciences Limited Stable pharmaceutical compositions of apomorphine
JP2025520542A (ja) 2022-06-15 2025-07-03 エバー ニューロ ファーマ ゲーエムベーハー アポモルヒネプロドラッグおよびその使用
WO2025259725A1 (en) * 2024-06-11 2025-12-18 Nano Pharmasolutions, Inc. Apomorphine compositions and therapeutic applications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
AU7260398A (en) * 1997-04-28 1998-11-24 University Of British Columbia, The Method and composition for modulating amyloidosis
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
HUP0400495A3 (en) * 1999-12-30 2007-05-02 Tap Pharmaceutical Prod Inc Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
AU2001269516B2 (en) * 2000-07-13 2006-09-14 Takeda Pharmaceutical Company Limited Lipid-rich plaque regressing agents
US20040028613A1 (en) * 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US20040126448A1 (en) * 2002-08-05 2004-07-01 Nils-Olof Lindberg Sexual dysfunction compounds
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution

Also Published As

Publication number Publication date
WO2006120412A1 (en) 2006-11-16
US8772309B2 (en) 2014-07-08
DK1885333T3 (da) 2012-05-14
KR20080016608A (ko) 2008-02-21
NO339404B1 (no) 2016-12-12
US20130131098A1 (en) 2013-05-23
ES2383433T3 (es) 2012-06-21
ZA200709474B (en) 2008-12-31
BRPI0611258A2 (pt) 2010-11-23
EP1885333B1 (de) 2012-02-15
NO20076219L (no) 2007-12-03
KR101365458B1 (ko) 2014-02-19
MX2007013890A (es) 2008-04-04
PT1885333E (pt) 2012-05-14
GB0509317D0 (en) 2005-06-15
CA2607802C (en) 2015-02-10
AU2006245564A1 (en) 2006-11-16
SI1885333T1 (sl) 2012-07-31
CN101217936A (zh) 2008-07-09
IL187183A0 (en) 2008-02-09
JP2008540392A (ja) 2008-11-20
HK1113086A1 (en) 2008-09-26
CA2607802A1 (en) 2006-11-16
JP5116665B2 (ja) 2013-01-09
EP1885333A1 (de) 2008-02-13
RU2007140701A (ru) 2009-06-20
US20090023766A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
BRPI0611705A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
EP1961748A3 (de) 2-Hydroxy-3-heteroarylindole Derivate als GSK3 Inhibitoren
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EP4442321A3 (de) Methoden zur behandlung von sjögren-syndrom mit einem hemmer von bruton-kinase
RU2009111378A (ru) Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
TW200639159A (en) Treatment of pain
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
EA200602016A1 (ru) ПОРОШКОВЫЕ КОМПОЗИЦИИ ДЛЯ ИНГАЛЯЦИИ, СОДЕРЖАЩИЕ ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ
TW200606164A (en) New compounds
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
TW200800984A (en) New compounds
EA200701615A1 (ru) Новые лекарственные средства для лечения заболеваний дыхательных путей
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto
TW200635925A (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
RU2009127858A (ru) Фармацевтическая композиция, включающая алискирен и авосентан
BRPI0512151A (pt) solução concentrada de sal de sódio monoidratado do tenatoprazol, composição farmacêutica, utilização do sal de sódio monoidratado do tenatoprazol, processo de preparação do sal de sódio monoidratado do tenatoprazol, e composição para administração por via oral do sal de sódio monoidratado do tenatoprazol
DE602005017629D1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis